Fate Therapeutics (FATE) Other Working Capital Changes (2017 - 2026)
Fate Therapeutics (FATE) posted Other Working Capital Changes of $200000.0 for Q1 2026, down 46.95% on a QoQ basis from $377000.0 in Q4 2025, and up 210.5% year-over-year from $64412.8 in Q1 2025.
Fate Therapeutics (FATE) Other Working Capital Changes (2017 - 2026) Analysis & Trends
Fate Therapeutics' Other Working Capital Changes history runs 10 years deep, the most recent figure standing at $200000.0 for Q1 2026.
- Quarterly Other Working Capital Changes rose 210.5% year-over-year to $200000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $369000.0 (up 167.34% YoY) and the FY2025 annual result came in at -$12000.0, up 98.65% from the prior year.
- Other Working Capital Changes was $200000.0 for Q1 2026 at Fate Therapeutics, down from $377000.0 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $7.4 million in Q4 2022 and bottomed at -$11.9 million in Q1 2023.
- A 5-year average of -$299647.1 and a median of $57000.0 in 2024 frame the typical range for Other Working Capital Changes.
- Annual changes were most pronounced in 2022 — Other Working Capital Changes soared 399.38% — and 2023, when it tumbled 1057.79%.
- Fate Therapeutics' Other Working Capital Changes stood at -$5.4 million in 2022, then jumped by 92.16% to -$425000.0 in 2023, then soared by 51.29% to -$207000.0 in 2024, then surged by 282.13% to $377000.0 in 2025, then plunged by 46.95% to $200000.0 in 2026.
- Business Quant data shows FATE's Other Working Capital Changes at $200000.0 in Q1 2026, $377000.0 in Q4 2025, and $4000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Fate Therapeutics | 302.48 Mn | 302.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 200,000.00 |
| Mar 31, 2026 | 200,000.00 |
| Mar 31, 2026 | 200,000.00 |
| Dec 31, 2025 | 377,000.00 |
| Dec 31, 2025 | 377,000.00 |
| Dec 31, 2025 | 377,000.00 |
| Sep 30, 2025 | 4,000.00 |
| Sep 30, 2025 | 4,000.00 |
| Sep 30, 2025 | 4,000.00 |
| Jun 30, 2025 | -212,000.00 |
| Jun 30, 2025 | -212,000.00 |
| Jun 30, 2025 | -212,000.00 |
| Mar 31, 2025 | -181,000.00 |
| Mar 31, 2025 | -181,000.00 |
| Mar 31, 2025 | -181,000.00 |
| Dec 31, 2024 | -207,000.00 |
| Dec 31, 2024 | -207,000.00 |
| Dec 31, 2024 | -207,000.00 |
| Jun 30, 2024 | -160,000.00 |
| Jun 30, 2024 | -160,000.00 |